• Sunstone analysis uses nearly 50,000 Phase III trials to gauge shifts in Big Pharma partnering or M&A appetite.
• Method compares sponsors with market caps above USD 10 billion versus others, split between recruiting trials and post-enrollment trials awaiting data.
• Big Pharma Concentration Index uses 1 as neutral representation; changes above 0.20 flagged as potentially significant.
• Psychiatry index rose to 1.26 from 0.28, signaling a sharp increase in large-cap drugmaker engagement.
• Autoimmune disease index increased to 1.85 from 1.53, indicating already elevated interest is still building.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunstone Life Science Ventures A/S published the original content used to generate this news brief on September 15, 2026, and is solely responsible for the information contained therein.